Birchview Capital as of June 30, 2023
Portfolio Holdings for Birchview Capital
Birchview Capital holds 54 positions in its portfolio as reported in the June 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bristol Myers Squibb (BMY) | 34.9 | $47M | 729k | 63.95 | |
| Prothena Corp SHS (PRTA) | 8.0 | $11M | 156k | 68.28 | |
| Neurocrine Biosciences (NBIX) | 6.0 | $7.9M | 84k | 94.30 | |
| Biodesix | 4.6 | $6.2M | 5.0M | 1.23 | |
| ACADIA Pharmaceuticals (ACAD) | 4.5 | $6.0M | 249k | 23.95 | |
| Quidel Corporation | 4.0 | $5.4M | 65k | 82.86 | |
| Aziyo Biologics (ELUT) | 2.9 | $3.9M | 1.7M | 2.36 | |
| ImmunoGen | 2.7 | $3.6M | 190k | 18.87 | |
| United Therapeutics Corporation (UTHR) | 2.5 | $3.3M | 15k | 220.75 | |
| Encana Corporation (OVV) | 2.4 | $3.2M | 84k | 38.07 | |
| Harrow Health (HROW) | 2.1 | $2.9M | 150k | 19.04 | |
| Phreesia (PHR) | 1.9 | $2.6M | 83k | 31.01 | |
| Masimo Corporation (MASI) | 1.9 | $2.5M | 15k | 164.55 | |
| Foghorn Therapeutics (FHTX) | 1.4 | $1.9M | 265k | 7.04 | |
| Inhibrx | 1.4 | $1.8M | 70k | 25.96 | |
| Accelr8 Technology | 1.4 | $1.8M | 2.3M | 0.81 | |
| Alkermes SHS (ALKS) | 1.2 | $1.6M | 50k | 31.30 | |
| Alphatec Holdings (ATEC) | 1.1 | $1.4M | 80k | 17.98 | |
| Equitrans Midstream Corp (ETRN) | 1.0 | $1.3M | 133k | 9.56 | |
| Corcept Therapeutics Incorporated (CORT) | 0.8 | $1.1M | 50k | 22.25 | |
| Apellis Pharmaceuticals (APLS) | 0.8 | $1.1M | 12k | 91.10 | |
| Soleno Therapeutics | 0.8 | $1.1M | 245k | 4.29 | |
| Protagonist Therapeutics (PTGX) | 0.8 | $1.0M | 38k | 27.62 | |
| Docgo (DCGO) | 0.8 | $1.0M | 110k | 9.37 | |
| Iveric Bio | 0.7 | $984k | 25k | 39.34 | |
| Stoke Therapeutics (STOK) | 0.7 | $904k | 85k | 10.63 | |
| Ventyx Biosciences (VTYX) | 0.6 | $866k | 26k | 32.80 | |
| Bluebird Bio | 0.6 | $820k | 249k | 3.29 | |
| Cytokinetics (CYTK) | 0.6 | $816k | 25k | 32.62 | |
| Pioneer Natural Resources | 0.6 | $787k | 3.8k | 207.18 | |
| 10x Genomics Cl A Com (TXG) | 0.5 | $670k | 12k | 55.84 | |
| Silk Road Medical Inc Common | 0.5 | $650k | 20k | 32.49 | |
| Travere Therapeutics (TVTX) | 0.5 | $614k | 40k | 15.36 | |
| 2seventy Bio | 0.5 | $606k | 60k | 10.12 | |
| Chinook Therapeutics | 0.4 | $576k | 15k | 38.42 | |
| Karyopharm Therapeutics | 0.4 | $522k | 291k | 1.79 | |
| Kiniksa Pharmaceuticals | 0.3 | $422k | 30k | 14.08 | |
| Xenon Pharmaceuticals (XENE) | 0.3 | $385k | 10k | 38.50 | |
| Arvinas Ord (ARVN) | 0.3 | $372k | 15k | 24.82 | |
| Axogen (AXGN) | 0.3 | $365k | 40k | 9.13 | |
| Halozyme Therapeutics (HALO) | 0.3 | $361k | 10k | 36.07 | |
| Kalvista Pharmaceuticals (KALV) | 0.3 | $360k | 40k | 9.00 | |
| Progyny (PGNY) | 0.3 | $354k | 9.0k | 39.34 | |
| Amicus Therapeutics (FOLD) | 0.3 | $352k | 28k | 12.56 | |
| Xencor (XNCR) | 0.2 | $307k | 12k | 24.97 | |
| Sarepta Therapeutics (SRPT) | 0.2 | $286k | 2.5k | 114.52 | |
| Keros Therapeutics (KROS) | 0.2 | $281k | 7.0k | 40.18 | |
| Cullinan Oncology (CGEM) | 0.2 | $270k | 25k | 10.76 | |
| Inflarx Nv (IFRX) | 0.2 | $223k | 50k | 4.46 | |
| BioCryst Pharmaceuticals (BCRX) | 0.1 | $141k | 20k | 7.04 | |
| Gossamer Bio (GOSS) | 0.1 | $119k | 99k | 1.20 | |
| G1 Therapeutics | 0.1 | $100k | 40k | 2.49 | |
| Yield10 Bioscience | 0.0 | $42k | 19k | 2.22 | |
| Nektar Therapeutics | 0.0 | $16k | 28k | 0.58 |
